NCT01988246View on ClinicalTrials.gov

Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 25, 2018

Study Completion Date

January 14, 2020

Conditions
Diabetic Retinopathy
Interventions
DRUG

Aflibercept

Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.

DRUG

Sham

Sham injection. No actual injection. No medication is used.

Trial Locations (1)

44195

Cole Eye Institute, Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Rishi Singh

OTHER

NCT01988246 - Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery | Biotech Hunter | Biotech Hunter